Editors:
- Covers the important new developments in clinical trial design and a number of important trial results that have resulted in new treatment options for patients and physicians *
- Important ethical considerations that arise with new treatments are included, as is a perspective on the emergence of MS as a treatable disease * Will be of interest to both specialists and general practitioners alike * Also will be of value to clinical epidemiologists and biostatisticians with an interest in experimental therapies for chronic disease, to immunologists with an interest in autoimmune disease, and to the pharmaceutical industry and to Multiple Sclerosis societies
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (16 chapters)
-
Front Matter
-
Back Matter
About this book
Editors and Affiliations
-
The UCSF/Mount Zion Multiple Sclerosis Center, University of California at San Francisco, San Francisco, USA
Donald E. Goodkin
-
Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, USA
Richard A. Rudick
Bibliographic Information
Book Title: Multiple Sclerosis
Book Subtitle: Advances in Clinical Trial Design, Treatment and Future Perspectives
Editors: Donald E. Goodkin, Richard A. Rudick
DOI: https://doi.org/10.1007/978-1-4471-1271-6
Publisher: Springer London
-
eBook Packages: Springer Book Archive
Copyright Information: Springer-Verlag London Limited 1996
Softcover ISBN: 978-1-85233-033-0Published: 26 May 1998
eBook ISBN: 978-1-4471-1271-6Published: 06 December 2012
Edition Number: 1
Number of Pages: XVIII, 364
Number of Illustrations: 4 b/w illustrations
Topics: Neurology, Internal Medicine, General Practice / Family Medicine